Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Receivables: 2016-2025

Historic Receivables for RedHill Biopharma (RDHL) over the last 6 years, with Jun 2025 value amounting to $5.3 million.

  • RedHill Biopharma's Receivables rose 449.28% to $5.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $11.5 million, marking a year-over-year decrease of 14.02%. This contributed to the annual value of $2.5 million for FY2024, which is 2.01% down from last year.
  • As of Q2 2025, RedHill Biopharma's Receivables stood at $5.3 million, which was up 110.71% from $2.5 million recorded in Q4 2024.
  • RedHill Biopharma's Receivables' 5-year high stood at $36.0 million during Q3 2022, with a 5-year trough of $974,000 in Q2 2024.
  • Over the past 3 years, RedHill Biopharma's median Receivables value was $2.7 million (recorded in 2023), while the average stood at $3.5 million.
  • As far as peak fluctuations go, RedHill Biopharma's Receivables spiked by 1,257.37% in 2021, and later plummeted by 92.49% in 2023.
  • RedHill Biopharma's Receivables (Quarterly) stood at $31.7 million in 2021, then climbed by 8.98% to $34.5 million in 2022, then crashed by 92.49% to $2.6 million in 2023, then fell by 2.01% to $2.5 million in 2024, then spiked by 449.28% to $5.3 million in 2025.
  • Its last three reported values are $5.3 million in Q2 2025, $2.5 million for Q4 2024, and $974,000 during Q2 2024.